3-丙酰苯甲腈 | 50916-34-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-丙酰苯甲腈
• 英文名称: 3-cyanopropiophenone
• 英文别名: 3-propionylbenzonitrile；3'-Cyano-propiophenon；3-Propanoylbenzonitrile
• CAS: 50916-34-2
• 化学式: C₁₀H₉NO
• 分子量: 159.188
• InChiKey: RQNDMQXNIOALFA-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  3-丙酰苯甲腈 在 溴 、 溶剂黄146 作用下， 反应 0.5h， 生成 3-[3-(3-Chloroanilino)-5-methyl-2-sulfanyl-imidazol-4-yl]benzonitrile
  参考文献：
  名称：

  N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action

  摘要：

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

  DOI：

  10.1021/jm0211117
• 作为产物：
  描述：

  3-硝基苯丙酮 在 盐酸 、 tin(ll) chloride 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 生成 3-丙酰苯甲腈
  参考文献：
  名称：

  Pratesi; Grana; Villa, Farmaco, Edizione Scientifica, 1973, vol. 28, # 10, p. 753 - 765

  摘要：

  DOI：

文献信息

• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• [EN] PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168260A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula wherein R1 is hydrogen or phenyl, optionally substitutes by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen or lower alkyl or is phenyl optionally substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; R4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式中的化合物，其中R1是氢或苯基，可选择由卤素、CN或较低的烷氧基或由卤素取代的较低的烷氧基取代；R2是氢或较低的烷基；R3是氢或较低的烷基或是苯基，可选择由卤素、氰基或由卤素取代的较低的烷氧基取代，或是吡啶基，可选择由卤素或由卤素取代的较低的烷基取代，或是嘧啶基，可选择由较低的烷基取代的较低的烷基取代，或是吡嗪基，可选择由卤素、氰基或由卤素取代的较低的烷基取代；R4是氢、较低的烷基或苯基；Z是键，-CH2-或-O-；或其药学上适宜的酸盐。现已发现，IA和IB式的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的疾病、如精神分裂症等精神疾病、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• PYRAZOLE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120316172A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula IA and IB wherein R 1 , R 2 , R 3 , R 4 and Z are as defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及式IA和IB的化合物，其中R1、R2、R3、R4和Z如本文所定义，或其药学上适宜的酸盐。式IA和IB的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• Structure-Based Design of Novel HIV Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors
  作者：Suvit Thaisrivongs、Keith D. Watenpaugh、W. Jeffrey Howe、Paul K. Tomich、Lester A. Dolak、Kong-Teck Chong、Che-Shen C. Tomich、Alfredo G. Tomasselli、Steve R. Turner

  DOI：10.1021/jm00018a023

  日期：1995.9

  biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl

  肽衍生的HIV蛋白酶抑制剂的低口服生物利用度和快速胆汁排泄限制了它们作为潜在治疗剂的用途。我们广泛的发现非肽类HIV蛋白酶抑制剂的筛选程序先前已将化合物II（苯普鲁蒙，K（i）= 1μM）鉴定为先导模板。包含肽衍生抑制剂I（1-（萘氧基乙酰基）-L-组氨酸5（S）-氨基-6-环己基-3（R），4（R）-二羟基-2（R）的HIV蛋白酶复合物的晶体结构）-异丙基己酰基-L-异亮氨酸N-（2-吡啶基甲基）酰胺）和非肽类抑制剂（如苯丙香酚（化合物II））为更多活性类似物的基于结构的设计提供了合理的基础。这项研究报告了重要的发现，即在功能上适当地添加到4-羟基香豆素和4-羟基-2-吡喃酮模板中的羧酰胺可产生一系列新的有希望的具有改善的酶结合亲和力的非肽类HIV蛋白酶抑制剂。含羧酰胺的化合物XXIV中活性最高的非对映异构体抑制HIV-1蛋白酶，其K（i）值为0.0014μM。这项研究为发现更有效的HI
• Photochemical rearrangement of α-chloro-propiophenones to α-arylpropanoic acids: studies on chirality transfer and synthesis of (S)-(+)-ibuprofen and (S)-(+)-ketoprofen
  作者：Harikisan R. Sonawane、Nanjundiah S. Bellur、Dilip G. Kulkarni、Nagaraj R. Ayyangar

  DOI：10.1016/s0040-4020(01)80835-8

  日期：1994.1

  α-arylpropanoic acids (4) from α chloro-propiophenones (5) is described. It involves carbonyl triplet excited state directed 1,2-aryl migration of the aryl group which has been found to be highly dependent upon the nature of the aryl substituent. The mode of this rearrangement is probed by the study of the photobehaviour of a set of optically active α-chloro-propiophenones. The results suggest that the nature of

  描述了一种新的单步高效光化学方法，可从α氯丙酮（5）中分离出α-芳基丙酸（4）。它涉及芳基的羰基三重激发态定向的1，2-芳基迁移，已发现其高度依赖于芳基取代基的性质。通过对一组光学活性的α-氯-苯乙酮的光行为的研究来探究这种重排的方式。结果表明，羰基三联体（n，π * /π，π *）的性质在手性转移中起重要作用。该方法在光学活性布洛芬（4e）和酮洛芬（26），尽管光学产量中等。